Study of AMT-676 combination therapy for advanced colorectal cancer
Treatments studied
Part of Cancer, Digestive system clinical trials.
This trial tests a new drug combination for people with advanced colorectal cancer that cannot be removed by surgery. It aims to see if the treatment can shrink tumors and help patients live longer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have advanced colorectal cancer that has spread and cannot be removed with surgery.
- You have at least one tumor that can be measured on a scan.
- You are well enough to be up and about (ECOG score 0 or 1).
- Your doctor expects you to live at least 6 months.
- Your organs (like kidneys, liver, and bone marrow) are working well.
- If you could have children, you agree to use effective birth control during and after treatment.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of two targeted therapies (QL1706 and bevacizumab) plus standard chemotherapy for people with a specific form of metastatic colorectal cancer that has a BRAF V600E mutation and is MSS/pMMR. The goal is to see if this triplet works better than standard treatment alone.
This trial tests a new combination of three drugs for people with advanced colorectal cancer that has not responded to previous treatments. The goal is to see if this combination can help shrink tumors or slow the cancer's growth.
This trial tests a combination of four drugs—bevacizumab, sintilimab, cetuximab, and irinotecan—in people whose colorectal cancer has spread and hasn't responded to previous treatments. The goal is to see if this new mix can shrink tumors or slow the cancer's growth.
This study tests a combination of several cancer drugs (irinotecan, capecitabine, bevacizumab, and camrelizumab) in people with metastatic colorectal cancer who have already tried at least one prior treatment. The goal is to see if these drugs work better together for patients who don't have certain genetic features.
This trial tests a new drug called AMT-676 in people with advanced solid tumors that have not responded to standard treatments. It may be an option for those with certain cancers like colorectal, stomach, or pancreatic cancer.
This trial tests a combination of three drugs (irinotecan liposomes, cetuximab, and vemurafenib) for people with advanced colorectal cancer that has a specific genetic change (BRAF V600E mutation) and did not respond to first treatment. The goal is to see if this combination can help shrink tumors or slow the cancer's growth.
Hear when a new Colorectal cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.